Hydromorphon Hexal (Hydromorphone Hydrochloride)

Hydromorphone acts as a selective agonist at μ‑opioid receptors in the brain and spinal cord. By activating these receptors, it reduces the release of pain‑transmitting neurotransmitters, dampening neuronal excitability and altering the perception of pain, which results in strong analgesic effects.

The appropriate dose of Hydromorphon Hexal is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, organ function, and concomitant medications. No fixed regimen is provided here; the prescriber sets the dose and titration schedule.

Safety data for hydromorphone in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and clinicians should discuss alternatives when possible.

To request Hydromorphon Hexal, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hydromorphon Hexal (hydromorphone) is a potent μ‑opioid receptor agonist, generally considered more potent on a milligram‑for‑milligram basis than morphine. It has a relatively rapid onset and shorter half‑life, which can be advantageous for titration, but it also shares similar safety considerations such as respiratory depression and dependence.

Store Hydromorphon Hexal at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Hydromorphon Hexal is formulated for oral administration. The tablet (or other oral dosage form) should be swallowed whole with water and taken exactly as prescribed. Patients should not crush, chew, or dissolve the product unless specifically instructed by a healthcare professional.

The most serious risks include respiratory depression, which can be life‑threatening, especially after dose escalation or when combined with other depressants; severe hypotension; and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these events occur.

Hydromorphon Hexal should be avoided in patients with known hypersensitivity to hydromorphone or any component of the formulation, in those with significant respiratory compromise, severe asthma, or untreated obstructive sleep apnea, and in individuals taking monoamine oxidase inhibitors within 14 days.